Home > Insider Trading > Filing (0000950170-25-018311)

Filing Details

Accession Number:: 0000950170-25-018311
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-02-11 21:30:58
Reporting Period:: 2025-02-10

Accepted Time:: 2025-02-11 21:30:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1778307	Andrew Cheng	C/O Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2025-02-10	12,640	$51.75	703,422	No	4	S	Direct
Common Stock	Disposition	2025-02-10	6,439	$52.91	696,983	No	4	S	Direct
Common Stock	Disposition	2025-02-10	9,972	$53.67	687,011	No	4	S	Direct
Common Stock	Disposition	2025-02-10	749	$54.55	686,262	No	4	S	Direct
Common Stock	Disposition	2025-02-10	200	$55.81	686,062	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $51.340 to $52.330, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.350 to $53.345, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.355 to $54.345, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.355 to $54.930, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.